Using Circulating Tumor DNA to Predict Treatment Response in Rectal Cancer
Author Information
Author(s): Mögele Tatiana, Höck Michael, Sommer Florian, Friedrich Lena, Sommer Sebastian, Schmutz Maximilian, Altenburger Amadeus, Messmann Helmut, Anthuber Matthias, Kröncke Thomas, Stüben Georg, Trepel Martin, Märkl Bruno, Dintner Sebastian, Claus Rainer, Becker Therese
Primary Institution: University Hospital of Augsburg
Hypothesis
Monitoring ctDNA changes during neoadjuvant chemoradiotherapy might help identify patients who achieve complete pathological response.
Conclusion
The NEORECT trial shows that while ctDNA monitoring is feasible, it does not reliably predict complete pathological response in rectal cancer patients undergoing treatment.
Supporting Evidence
- ctDNA patterns showed some correlation with treatment outcomes.
- Only one patient achieved complete pathological response despite ctDNA negativity.
- ctDNA alone demonstrated low specificity for predicting treatment response.
Takeaway
Doctors are trying to use blood tests to see how well treatment is working for rectal cancer, but it's not always accurate.
Methodology
The study collected plasma samples from rectal cancer patients before, during, and after treatment to analyze ctDNA dynamics.
Potential Biases
Potential bias due to the single-center design and limited participant diversity.
Limitations
The study had a small sample size and high dropout rate, which may affect the reliability of the findings.
Participant Demographics
Median age was 68 years, with 73% male participants.
Statistical Information
P-Value
0.01528
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website